[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100508393":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":23,"centralContacts":28,"locations":33,"responsibleParty":91,"collaborators":11,"id":93,"slug":94,"hasResults":95,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":99,"eligibilityCriteria":100,"healthyVolunteers":95,"sex":101,"minAge":102,"maxAge":11,"enrollmentInfo":103,"targetDuration":11,"studyType":106,"phases":107,"briefSummary":109,"conditions":110,"keywords":11,"overallStatus":36,"whyStopped":11,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":121},{"fullName":5,"class":6},"Centre Hospitalier Universitaire de Nīmes","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Systematic protein pump inhibitor therapy","EXPERIMENTAL",null,[13],"Drug: Protein pump inhibitor therapy systematically",{"label":15,"type":16,"description":11,"interventionNames":11},"Protein pump inhibitor therapy as necessary","NO_INTERVENTION",[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":11},"DRUG","Protein pump inhibitor therapy systematically","Lansoprazole 30mg once per day",[9],[24],{"name":25,"affiliation":26,"role":27},"Antoine Debourdeau","CHU de Nimes","PRINCIPAL_INVESTIGATOR",[29],{"name":25,"role":30,"phone":31,"phoneExt":11,"email":32},"CONTACT","06.68.31.94.89","a-debourdeau@chu-montpellier.fr",[34,53,65,76],{"facility":35,"status":36,"city":37,"state":11,"zip":11,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"AP-HM","RECRUITING","Marseille","France","FR",{"type":41,"coordinates":42},"Point",[43,44],5.38107,43.29695,{"lat":44,"lon":43},[47,51],{"name":48,"role":30,"phone":49,"phoneExt":11,"email":50},"Jean Michel Gonzalez","06.22.25.02.50","jean-michel.gonzalez@ap-hm.fr",{"name":52,"role":27,"phone":11,"phoneExt":11,"email":11},"ean Michel Gonzalez",{"facility":54,"status":36,"city":55,"state":11,"zip":11,"country":38,"countryCode":39,"cosmosGeoPoint":56,"geoPoint":60,"contacts":61},"CHU de Montpellier","Montpellier",{"type":41,"coordinates":57},[58,59],3.87635,43.61093,{"lat":59,"lon":58},[62,64],{"name":25,"role":30,"phone":31,"phoneExt":11,"email":63},"antoinedebourdeau@hotmail.com",{"name":25,"role":27,"phone":11,"phoneExt":11,"email":11},{"facility":66,"status":36,"city":55,"state":11,"zip":11,"country":38,"countryCode":39,"cosmosGeoPoint":67,"geoPoint":69,"contacts":70},"Clinique mutualiste Beausoleil",{"type":41,"coordinates":68},[58,59],{"lat":59,"lon":58},[71,75],{"name":72,"role":30,"phone":73,"phoneExt":11,"email":74},"Roman Combes","06.76.59.23.48","roman.combes@hotmail.fr",{"name":72,"role":27,"phone":11,"phoneExt":11,"email":11},{"facility":77,"status":36,"city":78,"state":11,"zip":11,"country":38,"countryCode":39,"cosmosGeoPoint":79,"geoPoint":83,"contacts":84},"CHU de Nîmes","Nîmes",{"type":41,"coordinates":80},[81,82],4.35788,43.83665,{"lat":82,"lon":81},[85,89],{"name":86,"role":30,"phone":87,"phoneExt":11,"email":88},"Anissa Megzari","04.66.68.42.36","drc@chu-nimes.fr",{"name":90,"role":27,"phone":11,"phoneExt":11,"email":11},"Ludovic Caillo",{"type":92,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100508393","routine-versus-symptomatic-protein-pump-inhibitor-therapy-for-prevention-of-gastroesophageal-reflux-after-per-oral-endoscopic-myotomy-for-esophageal-achalasia-100508393",false,"NCT05899842","Routine Versus Symptomatic Protein Pump Inhibitor Therapy for Prevention of Gastroesophageal Reflux After Per Oral Endoscopic Myotomy for Esophageal Achalasia","Routine Versus Symptomatic Protein Pump Inhibitor Therapy for Prevention of Gastroesophageal Reflux After Per Oral Endoscopic Myotomy for Esophageal Achalasia. Randomized Open-label Clinical Trial","IPPOEM","Inclusion Criteria:\n\n* Patient with an indication for esophageal POEM for achalasia\n* Patient with all types of achalasia with Eckardt score \\> 3\n* The patient must have given their free and informed consent and signed the consent form\n* The patient must be a member or beneficiary of a health insurance plan\n\nExclusion Criteria:\n\n* Patient with contraindications to PPIs\n* Patient with mediastinal and esophageal neoplasia\n* Patient with a history of Heller myotomy surgery\n* Patients requiring any type of anti-reflux valve surgery\n* The subject is in a period of exclusion determined by a previous study\n* It is impossible to give the subject informed information\n* The patient is under safeguard of justice or state guardianship\n* Patient is pregnant, parturient or breastfeeding","ALL","18 Years",{"count":104,"type":105},132,"ESTIMATED","INTERVENTIONAL",[108],"NA","Per Oral Endoscopic Myotomy (POEM) is a treatment of choice for achalasia with an excellent safety and efficacy profile. There is a high rate of esophagitis related to gastroesophageal reflux following this procedure. There is no recommendation on the prescription of protein pump inhibitors (PPI) after the procedure and no study has studied the benefit of systematic prescription of PPI after POEM for achalasia. The study authors hypothesize that routine PPI prescribing post-POEM for 12 months would reduce the rate of esophageal acid exposure compared to a symptom-based prescribing strategy.",[111],"Esophageal Achalasia","2026-02-06",{"date":114,"type":115},"2026-02-10","ACTUAL",{"date":117,"type":115},"2023-06-01",{"date":119,"type":105},"2028-02",{"name":5,"class":6},4]